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M
etabolic regulation and immune signaling are
closely linked, as evidenced by both the
physical proximity between metabolic cells
(e.g., adipocytes and hepatocytes) and resident
macrophages as well as the progression of inﬂammation in
metabolic syndrome. Contrasting the reactions to pathogen
infections, meta-inﬂammation describes a novel type of low-
grade, unresolvable immune response that is in the causal
pathway to metabolic dysregulation (1). Although how meta-
inﬂammation is initiated remains unclear, the T-helper cell
type 1 (Th1)/Th2 (or M1/M2) paradigm provides a simpliﬁed
view of how immune cells are involved in readjusting
metabolic set points in response to nutrient intake (2). It
appears that Th1 cytokines (e.g., interleukin [IL]-12 and
interferon-g [IFNg]) or Th1 polarized immune cells pro-
mote insulin resistance, whereas Th2 signaling (e.g., IL-4
and IL-13) sustains metabolic homeostasis (3). In mouse
genetic models, for example, tipping the Th1/Th2 balance
toward one speciﬁc spectrum leads to the expected out-
come (4). As such, immunometabolism has become an at-
tractive target to treat metabolic diseases.
Members of the signal transducer and activator of the
transcription (STAT) family are transcription factors that
mediate the signaling events of many cytokines in immune
and nonimmune cells (5–7). The seven mammalian STAT
proteins each contain a DNA-binding domain, a trans-
activation domain, and an Src homology 2 (SH2) domain;
the latter is required for dimerization (5). When cytokines
are bound to cell surface receptors, the associated Janus
kinases (JAKs) are activated, leading to tyrosine phos-
phorylation of the given STAT proteins (5). Phosphory-
lated STATs form dimers, translocate to the nucleus, and
bind speciﬁc response elements to activate transcription of
target genes (6). Previous work has provided a good un-
derstanding of the function of STAT proteins in in-
ﬂammation (7). More recently, alternative roles have been
described for STATs in direct regulation of metabolic
processes in a variety of tissues (Fig. 1). For example,
activation of STAT1 by IFNg facilitates M1 macrophage
polarization in adipose tissue, an underlying mechanism of
insulin resistance (4,8). Not surprisingly, due to its critical
role in IFN-induced responses, STAT1 also contributes
to autoimmune b-cell death in the development of type 1
diabetes (9). In contrast, the IL-4/IL-13-STAT6 signaling
pathway is required to maintain alternative macrophage
polarization in healthy white adipose tissue (3). STAT6-
deﬁcient mice are more susceptible to developing insulin
resistance and glucose intolerance when challenged with
a high-fat diet despite less weight gain (10). In hepatocytes,
IL-13 has been shown to suppress glucose production
through a noncanonical, STAT3-dependent pathway (11).
The emerging function of STAT proteins in direct metabolic
regulation further underscores the intricate relationship
between immune and metabolic pathways and implicates
their potential to serve as therapeutic targets.
In this issue, Dobrian et al. (12) implicate STAT4 in the
development of white adipose tissue (WAT) inﬂammation
and insulin resistance. STAT4 is primarily activated by
IL-12 to promote cytotoxic responses and Th1 cell differ-
entiation. Consequently, STAT4 gene deletion leads to a
Th2-biased phenotype (7). Dobrian et al. show that STAT4-
deﬁcient mice have improved insulin sensitivity and glucose
tolerance when challenged with a high-fat diet. As expected,
STAT4
2/2 WAT shows less macrophage inﬁltration with an
M2 polarization phenotype, an observation that is likely due
to a reduction in IFNg-producing T cells. There is also an
increase in CD3
+CD25
+ T-regulatory cells and a decrease
in CD8
+ T cells. CD4
+ cells are not affected. These results
are consistent with a previous study that implicated CD8
+
T cells in macrophage recruitment, adipose tissue inﬂam-
mation, and systemic insulin resistance (13).
Interestingly, STAT4 appears to play a speciﬁcr o l ei n
CD8
+ T-cell migration into adipose tissue. Two lines of
evidence support this notion. First, IL-12 induces the pro-
duction of CXCL10 and CCL5—chemokines that attract T
cells—in WAT explants in a STAT4-dependent manner.
Conditioned media from STAT4-deﬁcient WAT explants
were less effective at recruiting both CD4
+ and CD8
+
T cells. In addition, CD8
+ T cells derived from STAT4
2/2
mice showed a signiﬁcant reduction in their migratory
activities, indicating an intrinsic defect in migration. In-
deed, expression of CCR3 and CCR5, which could serve as
CCL5 receptors, is downregulated in STAT4-deﬁcient
CD8
+ cells. To further evaluate this function of STAT4,
Dobrian et al. reconstituted Rag1 mice, which lack T, NKT,
and B cells, with splenocytes of STAT4
2/2 mice and wild-
type controls. Mice receiving STAT4-deﬁcient splenocytes
are more insulin sensitive and exhibit reduced WAT CD8
+
T cells. However, the improvement is milder compared
with that observed with whole-body STAT4 deﬁciency.
Results from this study suggest that STAT4 activation
in CD8
+ T cells may be one of the initial cues triggering
immune cell migration into adipose tissue. Anatomically,
WAT CD8
+ T cells appear to be speciﬁcally affected by
STAT4 deﬁciency. Dobrian et al. demonstrate STAT4 is ex-
pressed in adipocytes, indicating that adipose STAT4 is
also involved in CD8
+ T-cell recruitment/activation. In line
with this notion, STAT4
2/2 fat explants were nonresponsive
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COMMENTARYto IL-12–stimulated chemokine production, as described
earlier. Furthermore, the splenocyte reconstitution experi-
ment suggests that STAT4 in nonhematopoietic cells may
also contribute to meta-inﬂammation. Approaches using
conditional knockout models will be required to assess the
tissue/cell type–speciﬁc function of STAT4. Another im-
portant question that deserves investigation is the source
of IL-12 in WAT. M1 macrophages can produce IL-12.
However, CD8
+ T-cell inﬁltration is thought to precede that
of the M1 macrophage (13). Dobrian et al. (12) show re-
duced expression of IL-12 p35 and p40 subunits in STAT4
2/2
adipocytes. It will be interesting in future work to deter-
mine whether adipose STAT4 regulates feed-forward, IL-12
autocrine signaling in initiating meta-inﬂammation, and
whether pharmacologic inhibition of the IL-12/STAT4
pathway suppresses the WAT inﬂammatory response to
improve metabolic homeostasis and insulin sensitivity.
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FIG. 1. STAT proteins in regulation of metabolic tissue homeostasis.
The Th1/Th2 or M1/M2 paradigm describes how immune signaling mod-
ulates metabolic homeostasis, notably within adipose tissues. Phos-
phorylated STAT1 (pSTAT1) regulates M1 polarization of macrophages
in response to Th1 cytokines, while pSTAT6 promotes M2 polarization.
Additionally, Th2 cytokines activate pSTAT3 in the liver to suppress
expression of gluconeogenic genes. Results from Dobrian et al. (12)
suggest that the combined function of pSTAT4 in adipocytes and T cells
leads to increased CD8
+ cell inﬁltration into WAT, where CD8
+ cell–de-
rived IFNg mediates recruitment and activation of M1 macrophages,
thereby contributing to metabolic dysfunction.
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